Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Amortizatization of Intangibles (2023 - 2025)

Historic Amortizatization of Intangibles for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to $357000.0.

  • Artiva Biotherapeutics' Amortizatization of Intangibles fell 4582.7% to $357000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 6620.34%. This contributed to the annual value of $2.3 million for FY2024, which is 41359.65% up from last year.
  • Artiva Biotherapeutics' Amortizatization of Intangibles amounted to $357000.0 in Q3 2025, which was down 4582.7% from $509000.0 recorded in Q2 2025.
  • Artiva Biotherapeutics' Amortizatization of Intangibles' 5-year high stood at $1.0 million during Q4 2024, with a 5-year trough of $159000.0 in Q3 2023.
  • Over the past 3 years, Artiva Biotherapeutics' median Amortizatization of Intangibles value was $368000.0 (recorded in 2024), while the average stood at $485888.9.
  • Per our database at Business Quant, Artiva Biotherapeutics' Amortizatization of Intangibles surged by 31446.54% in 2024 and then crashed by 4582.7% in 2025.
  • Over the past 3 years, Artiva Biotherapeutics' Amortizatization of Intangibles (Quarter) stood at $283000.0 in 2023, then skyrocketed by 268.2% to $1.0 million in 2024, then tumbled by 65.74% to $357000.0 in 2025.
  • Its last three reported values are $357000.0 in Q3 2025, $509000.0 for Q2 2025, and $723000.0 during Q1 2025.